Peculiarities of hemostasis in patients with COVID-19

Aim. Analysis of the dynamics of different stages of clot formation and its lysis in patients with different COVID-19 severity. Materials and methods. We prospectively included 58 patients with COVID-19 (39 patients with moderate disease severity and 18 patients with severe disease) and 47 healthy v...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Terapevtic̆eskii arhiv 2022-08, Vol.94 (7), p.876-883
Hauptverfasser: Kalinskaya, Anna I., Dukhin, Oleg A., Molodtsov, Ivan A., Anisimova, Aleksandra S., Sokorev, Denis A., Elizarova, Antonina K., Sapozhnikova, Olga A., Glebova, Kseniya A., Shakhidzhanov, Soslan S., Spiridonov, Ilia S., Ataullakhanov, Fazly I., Shpektor, Alexander V., Vasilieva, Elena Yu
Format: Artikel
Sprache:rus
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim. Analysis of the dynamics of different stages of clot formation and its lysis in patients with different COVID-19 severity. Materials and methods. We prospectively included 58 patients with COVID-19 (39 patients with moderate disease severity and 18 patients with severe disease) and 47 healthy volunteers as a control group. All participants underwent the assessment of flow-mediated dilation (FMD) of brachial artery, impedance aggregometry, rotational thromboelastometry and thrombodynamics. Von Willebrand factor antigen (vWF:Ag) quantification was also performed in patients with COVID-19. Measurements were repeated on the 3rd and 9th day of hospitalization. Results. Compared to the control group, patients with COVID-19 showed reduced values of platelet aggregation and greater values of the clot growth rate, as well as its size and density. On the first day of hospitalization, we found no differences in the activity of plasma hemostasis and endogenous fibrinolysis between subgroups of patients. With the progression of the disease, the growth rate and size of the clot were higher in the severe subgroup, even despite higher doses of anticoagulants in this subgroup. An increase in platelet aggregation was noted during the progression of the disease, especially in the severe subgroup. There were no differences in the results of the FMD test by subgroups of patients. The vWF:Ag level was significantly higher in the severe subgroup. Conclusion. Thus, plasma hemostasis followed by secondary platelet activation correlates with the severity of COVID-19. Patients with moderate to severe coronavirus infection have predominantly local rather than generalized endothelial dysfunction.
ISSN:0040-3660
2309-5342
DOI:10.26442/00403660.2022.07.201754